[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 46 of about 46
1. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ, Nevill TJ: High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood; 2005 Aug 15;106(4):1473-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.
  • Beginning in 1985, patients in British Columbia with Hodgkin lymphoma (HL) that was not controlled by conventional chemotherapy routinely underwent high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT).
  • Long-term complications of HD-ASCT have become apparent as more patients survive without recurrence of HL.
  • Data were obtained retrospectively on the first 100 patients that underwent HD-ASCT for HL in Vancouver, focusing on relapse, treatment-related complications, and the occurrence of late events.
  • OAS was significantly better in patients in first relapse (67%) than in patients with primary refractory-induction failure (39%) and advanced disease (29%) (P = .002).
  • Karnofsky performance status was at least 90% in 47 patients although hypogonadism (20 patients), hypothyroidism (12 patients), unusual infections (10 patients), anxiety or depression (7 patients), and cardiac disease (5 patients) were not uncommon in survivors.
  • HD-ASCT can lead to durable remissions in relapsed or refractory HL with acceptable but definite late toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Canada. Cause of Death. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / mortality. Probability. Retrospective Studies. Salvage Therapy. Survival Rate. Transplantation, Autologous. Treatment Outcome


2. Shamash J, Powles T, Ansell W, Berney D, Stebbing J, Mutsvangwa K, Wilson P, Asterling S, Liu S, Wyatt P, Joel SP, Oliver RT: GAMEC--a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours. Br J Cancer; 2007 Aug 6;97(3):308-14
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GAMEC--a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours.
  • There is no consensus as to the management of untreated poor prognosis or relapsed/refractory germ cell tumours.
  • We have studied an intensive cisplatin-based regimen that incorporates high-dose methotrexate (HD MTX) and actinomycin-D and etoposide every 14 days (GAMEC).
  • PK values were not predictive of efficacy or toxicity, although the dose intensity in the pretreated group of patients, especially of HD MTX, was significantly correlated with progression-free survival (PFS).
  • [MeSH-minor] Adolescent. Adult. Dactinomycin / administration & dosage. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Humans. Methotrexate / administration & dosage. Middle Aged. Prognosis. Recurrence. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):178-84 [15999102.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1987;4(1):33-7 [3037206.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6549-55 [16170162.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):27-32 [2153192.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1163-72 [1710655.001]
  • [Cites] Eur J Cancer. 1992;28(1):86-91 [1373636.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1427-35 [8021734.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2559-63 [9215825.001]
  • [Cites] Ann Oncol. 1997 May;8(5):477-83 [9233528.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):692-701 [9469359.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):289-93 [10355572.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1392-9 [10424741.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):685-92 [10442191.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6999-7004 [16192587.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):531-3 [16234294.001]
  • [Cites] Lancet. 2006 Mar 4;367(9512):754-65 [16517276.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5403-7 [17135640.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5893-9 [16115931.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1173-80 [10715285.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3346-51 [11013274.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):81-8 [11134198.001]
  • [Cites] Lancet. 2001 Mar 10;357(9258):739-45 [11253966.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):871-7 [12610187.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1869-75 [12673712.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):601-6 [14760371.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1724-33 [15073863.001]
  • [Cites] South Med J. 1976 Aug;69(8):1017-21 [986690.001]
  • [ErratumIn] Br J Cancer. 2007 Oct 22;97(8):1188. Berney, Dan [added]
  • (PMID = 17609665.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2360316
  •  go-up   go-down


3. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E: Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant; 2005 Sep;11(9):688-97
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
  • To achieve long-term disease-free survival, high-dose therapy and autologous stem cell transplantation (ASCT) is the current standard approach in patients with relapsed or refractory Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL).
  • In this phase II study, 49 patients with relapsed or refractory HD (n = 22) and NHL (n = 27) with a median age of 42 years were treated with an IIVP salvage regimen consisting of ifosfamide, idarubicin, and etoposide.
  • Twenty-seven percent of the patients had primary refractory disease, whereas 22% and 51% had early and late relapses, respectively.
  • As analyzed by intention to treat, 16 patients (33%) achieved complete remission and 21 patients (43%) achieved a partial response, leading to an overall response rate of 76% (63% in NHL and 91% in HD).
  • In the univariate analysis, diagnosis (HD versus NHL), remission duration before the initiation of IIVP, disease bulk, increased lactate dehydrogenase, and the presence of "B" symptoms were significant factors affecting the response achieved by the IIVP regimen.
  • In patients with HD, 4-year EFS and 4-year OS were 54.9% and 70.6%, respectively, without a significant difference with respect to the survival rates obtained in patients with NHL (43.6% and 63.6%, respectively).
  • The IIVP regimen is a highly effective salvage regimen for patients with relapsed or refractory HD or NHL who are candidates for ASCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Salvage Therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Case-Control Studies. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Middle Aged. Recurrence. Transplantation, Homologous

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125639.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide; ZRP63D75JW / Idarubicin
  •  go-up   go-down


Advertisement
4. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, Falk PM, Rosenthal J, Alvarnas J, Forman SJ: Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood; 2005 Jan 15;105(2):874-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment of HIV-associated lymphoma has changed since the widespread use of highly active antiretroviral therapy.
  • This has led to higher response rates in patients with HIV-associated Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) treated with chemotherapy in conjunction with antiretroviral therapy.
  • However, for patients with refractory or relapsed disease, salvage chemotherapy still offers little chance of long-term survival.
  • In the non-HIV setting, patients with relapsed Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) have a better chance of long-term remission with high-dose chemotherapy with autologous stem cell rescue (ASCT) compared with conventional salvage chemotherapy.
  • With long-term follow-up we demonstrate that ASCT can lead to an 85% progression-free survival, which suggests that this approach may be potentially curative in select patients with relapsed HIV-associated HD or NHL.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. CD4 Lymphocyte Count. Child. Disease-Free Survival. Follow-Up Studies. Humans. Middle Aged. Recurrence. Remission Induction. Risk Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15388574.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI38592; United States / NCI NIH HHS / CA / CA30206; United States / NCI NIH HHS / CA / CA33572
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


5. Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, Chandramouly A, Verma S, Kothari P, Coleman M: FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer; 2006 Dec 1;107(11):2678-87
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
  • The objective of this study was to determine the predictive value of FDG-PET as an early response indicator after 1 cycle of chemotherapy for progression-free survival (PFS) in diffuse large cell lymphoma (DLCL) and classic Hodgkin disease (HD).
  • Fourteen of 16 PET-positive patients after 1 cycle had refractory disease or relapsed (median PFS, 5.5 months).
  • CONCLUSIONS: FDG-PET had a high prognostic value after 1 cycle of chemotherapy, thus it can be a valid alternative for posttreatment evaluation of DLCL and HD and may offer the potential for change in treatment paradigms.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Fluorodeoxyglucose F18. Hodgkin Disease / drug therapy. Hodgkin Disease / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Iodine Radioisotopes. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Predictive Value of Tests. Prednisone / administration & dosage. Retrospective Studies. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17063502.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


6. Wadehra N, Farag S, Bolwell B, Elder P, Penza S, Kalaycio M, Avalos B, Pohlman B, Marcucci G, Sobecks R, Lin T, Andrèsen S, Copelan E: Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant; 2006 Dec;12(12):1343-9
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
  • Busulfan (Bu)-based preparative regimens have not been extensively investigated in Hodgkin disease (HD).
  • The purposes of this study were to investigate the toxicity and efficacy of a novel preparative regimen of Bu 14 mg/kg, etoposide 50-60 mg/kg, and cyclophosphamide 120 mg/kg in patients with primary refractory and relapsed HD.
  • A Cox proportional hazards model identified refractory disease at time of transplantation as the only significant factor affecting relapse and overall survival, whereas disease bulk >10 cm affected overall survival.
  • This novel Bu regimen is comparable to other radiation-free preparative regimens in its effectiveness in the control of HD and with a low-risk of early treatment-related mortality.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Peripheral Blood Stem Cell Transplantation / statistics & numerical data. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Busulfan / administration & dosage. Busulfan / adverse effects. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Lung Diseases / etiology. Lung Diseases / mortality. Male. Middle Aged. Myelodysplastic Syndromes / etiology. Myelodysplastic Syndromes / mortality. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / mortality. Postoperative Complications / etiology. Postoperative Complications / mortality. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Analysis. Transplantation, Autologous. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Biol Blood Marrow Transplant. 2007 Jun;13(6):746-7 [17531785.001]
  • (PMID = 17162217.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


7. Glossmann JP, Staak JO, Nogova L, Diehl V, Scheid C, Kisro J, Reis HE, Peter N, Engert A, Josting A: Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. Ann Hematol; 2005 Aug;84(8):517-25
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
  • Patients with primary progressive or refractory Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma (NHL) have a particularly poor prognosis.
  • Patients aged 18-55 years with primary progressive or refractory relapsed HD and aggressive NHL were included.
  • Patients with bulky disease (>5 cm) or residual lymphoma received involved field radiotherapy.
  • Twenty-five patients were included (HD=10, NHL=15, median age 34 years).
  • Two patients with HD achieved a CR and five patients a PR [response rate (RR) 70%].
  • Of the eight patients (56%) with treatment failure, three had progressive disease and five died from peritransplant complications.
  • [MeSH-major] Lymphoma / therapy. Peripheral Blood Stem Cell Transplantation / methods. Salvage Therapy / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Male. Middle Aged. Probability. Remission Induction. Survival Analysis. Transplantation, Autologous. Treatment Failure

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15759115.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Minigo H, Vrhovac R, Kalac M, Jaksić B: [Autologous stem cell transplantation in patients with relapsed or refractory Hodgkin's disease]. Acta Med Croatica; 2009 Jun;63(3):215-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous stem cell transplantation in patients with relapsed or refractory Hodgkin's disease].
  • Patients with relapsed or refractory Hodgkin's disease (HD) are routinely treated with intensive chemotherapy followed by autologous stem cell transplantation (ASCT).
  • From February 1995 until October 2006, a total of 53 patients with active HD (28 male and 25 female, aged 18-60, median 29) received BEAM myeloablative treatment followed by ASCT.
  • Accordingly, in this group of patients with active disease at the time of transplantation, ASCT toxicity could be considered acceptable.
  • We conclude that BEAM myeloablative chemotherapy followed by ASCT is a very efficacious treatment for patients with relapsed or refractory HD.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Recurrence. Survival Rate. Transplantation Conditioning. Transplantation, Autologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827348.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


9. Abali H, Oyan B, Koc Y, Kars A, Barista I, Uner A, Turker A, Demirkazik F, Tekin F, Tekuzman G, Kansu E: IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. Am J Clin Oncol; 2005 Jun;28(3):264-9
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
  • Patients with relapsed lymphoma can be cured with high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT).
  • New therapeutic approaches with better cytoreductive capacity are needed for relapsed patients to keep their chance for cure with transplantation.
  • We report 30 patients with relapsed lymphoma, median age 43 years, treated with IIVP salvage regimen consisting of ifosfamide, mesna, idarubicin, and etoposide for 2 or 3 cycles.
  • Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD).
  • Overall response rate was 92% in patients with HD and 82% in NHL.
  • IIVP regimen is a highly effective salvage therapy for patients with relapsed HD or NHL who are candidates for autologous HSCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy. Peripheral Blood Stem Cell Transplantation. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Hodgkin Disease / drug therapy. Hodgkin Disease / surgery. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Infection / etiology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Neutropenia / chemically induced. Recurrence. Remission Induction. Thrombocytopenia / chemically induced. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923799.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide; ZRP63D75JW / Idarubicin; IIVP-16
  •  go-up   go-down


10. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E: High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma; 2006 Aug;47(8):1545-52
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
  • Although high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL), more than 50% of patients will experience relapse following ASCT.
  • We conducted a phase II study in 40 patients with relapsed/refractory HD (n = 18) and NHL (n = 22) using HDSC followed by ASCT.
  • Eleven out of nineteen patients with B-cell lymphoma received rituximab.
  • At a median follow-up of 32 months (range, 3 - 61), nine patients relapsed/progressed and eleven patients died.
  • The estimated 4-year PFS and overall survival (OS) were 72.2% and 47.6% in HD patients and 70.3% and 69.4% in NHL patients, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma / therapy. Peripheral Blood Stem Cell Transplantation / methods. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Etoposide / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Melphalan / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Remission Induction. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966265.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


11. Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N: Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest; 2008 May;26(4):401-6
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
  • BACKGROUND: High dose chemotherapy with autologous stem cell transplantation is currently the treatment of choice for relapsed or refractory lymphoma patients.
  • In this study, our aim was to compare the efficacy and toxicity profiles of DHAP (cytosine arabinoside, cisplatin and dexamethasone) and ICE (ifosfamide, carboplatin and etoposide) regimens in the salvage treatment of relapsed and refractory lymphoma.
  • PATIENTS AND METHODS: In this retrospective analysis, 53 patients with primary refractory or relapsed Hodgkin's disease (HD) (n = 13) or non-Hodgkin lymphoma (NHL) (n = 40) who received ICE or DHAP salvage regimen were included.
  • Response could be evaluated in 49 patients (36 NHL and 13 HD).
  • CONCLUSION: Although the toxicity profiles of both ICE and DHAP regimens were similar in the treatment of patients with relapsed or refractory HD or NHL, ICE seems to have higher rates of response than DHAP regimen does.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Carboplatin / administration & dosage. Carboplatin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cohort Studies. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Immunotherapy. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Recurrence. Remission Induction. Retrospective Studies. Rituximab. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443961.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; DHAP protocol; ICE protocol 3
  •  go-up   go-down


12. Wendland MM, Asch JD, Pulsipher MA, Thomson JW, Shrieve DC, Gaffney DK: The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol; 2006 Apr;29(2):189-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease.
  • OBJECTIVES: Patients with refractory/relapsed Hodgkin disease (HD) often receive high-dose chemotherapy (HDCT) followed by hematopoietic progenitor cell transplant (HPCT) as salvage therapy.
  • METHODS: The records of 65 patients with refractory/relapsed HD who underwent HDCT followed by HPCT between September 1988 and October 2003 were retrospectively reviewed.
  • IFRT patients were more likely to have bulky disease at initial diagnosis (P = 0.05).
  • There was no significant difference between the treatment groups regarding mortality in the first 100 days after HPCT (P = 0.41), late events (P = 0.26), or failure in sites previously involved with disease (P = 0.76).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16601441.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E: High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemother Pharmacol; 2007 May;59(6):771-9
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
  • OBJECTIVE: High dose (HD) Ara-C combined with a single HD idarubicin dose (IDA) is an efficient and safe salvage regimen for patients with refractory or relapsed acute lymphoblastic leukemia as indicated by phase II studies.
  • No data are available on the pharmacokinetics of IDA after a rapid HD intravenous infusion.
  • An open phase II pharmacokinetic and clinical study was performed to evaluate antileukemic efficacy, IDA pharmacokinetics and to investigate the presence of IDA and its reduced metabolite idarubicinol (IDAol) in cerebrospinal fluid (CSF) of patients treated with HD-IDA.
  • PATIENTS AND METHODS: Twenty-five patients with refractory or relapsed acute lymphoblastic leukemia received Ara-C 3 g/m2 from days 1-5, idarubicin (HD-IDA) 40 mg/m2 as rapid intravenous (i.v.) infusion on day 3 and subcutaneous G-CSF 5 microg/kg from day 7 until PMN recovery.
  • Pharmacokinetics of IDA was evaluated after HD idarubicin administration in nine of these patients.
  • RESULTS: Eleven patients (44%, 95% CI: 23-65%) achieved complete remission with median disease free survival for 6 months.
  • After administration of HD-IDA i.v. bolus of 40 mg/m2, plasma level profiles of unchanged drug and IDAol were similar to those previously described after standard dose and measured with the same analytical method.
  • IDAol t1/2 was also similar after HD-IDA (46.2 h) and standard dose (39.4 h, P=0.79).
  • Furthermore, HD infusion resulted in a ratio between the AUC of parent drug and idarubicinol not different from the value observed with the standard-dose.
  • The IDA exposure lower than expected may explain the safety of the single i.v. administration of 40 mg/m2 of IDA, combined with HD Ara-C, with a degree of myelosuppression equivalent to that reported with this agent administered in standard doses.
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Recurrence. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256136.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


14. Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Müller RP, Diehl V, Engert A: Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol; 2005 Mar 1;23(7):1522-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
  • PURPOSE: To evaluate treatment outcome and prognostic factors in patients with refractory or first relapsed Hodgkin's disease (HD) treated with salvage radiotherapy (SRT) alone.
  • PATIENTS AND METHODS: From 4,754 patients registered in the database of the German Hodgkin Study Group from 1988 to 1999, 624 patients were identified with progressive disease (n = 202), or with early (n = 170) or late (n = 252) relapsed HD.
  • Patient characteristics were: median age, 36 years; progressive disease, 47%; early relapse, 23%; late relapse, 30%; and "B" symptoms, 14%.
  • Eighty-five percent of the patients relapsed after cyclophosphamide, vincristine, procarbazine, and prednisone/doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP/ABVD) -like regimens; 8% after bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) regimens, 7% after first-line radiotherapy alone.
  • CONCLUSION: SRT offers an effective treatment for selected subsets of patients with relapsed or refractory HD.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Male. Middle Aged. Prednisone / therapeutic use. Procarbazine / therapeutic use. Radiotherapy / adverse effects. Retrospective Studies. Survival Rate. Treatment Failure. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632410.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; COPP protocol
  •  go-up   go-down


15. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scimè R, Narni F, Pogliani E, Locasciulli A, Milani R, Carniti C, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni AM, Tarella C, Gruppo Italiano Trapianto di Midollo Osseo: Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia; 2007 Nov;21(11):2316-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.
  • The safety and efficacy of reduced-intensity conditioning (RIC) followed by allogeneic stem cell transplantation (SCT) for relapsed lymphomas remains unresolved.
  • A total of 170 relapsed/refractory lymphomas received a RIC regimen followed by SCT from sibling donors.
  • Histologies were non-Hodgkin's lymphomas (NHL) (indolent (LG-NHL), n=63; aggressive (HG-NHL), n=61; mantle cell lymphoma (MCL), n=14) and Hodgkin's disease (HD, n=32).
  • The results show that frequencies were as follows: cumulative NRM at 3 years, 14%; acute and chronic graft-versus-host disease (GVHD) 35 and 52%, respectively; 3-year overall survival (OS), 69% for LG-NHL, 69% for HG-NHL, 45% for MCL and 32% for HD (P=0.058); and 3-year relapse incidence, 29, 31, 35 and 81%, respectively (P<0.001).
  • Relapse risk differed significantly at 3 years between follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) (14 versus 46%, P=0.04).
  • On multivariate analysis, OS was influenced by chemorefractory disease (hazard ratio (HR)=3.6), diagnosis of HD (HR=3.5), and acute GVHD (HR=5.9).
  • [MeSH-major] Lymphoma / therapy. Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Stem Cells / cytology. Stem Cells / metabolism. Time Factors. Transplantation, Homologous / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597807.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


16. Gutiérrez-Aguirre CH, Ruiz-Argüelles G, Cantú-Rodríguez OG, González-Llano O, Jaime-Pérez JC, García-Rodríguez F, López-Otero A, Herrera-Garza JL, Gómez-Almaguer D: Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Ann Hematol; 2010 Oct;89(10):1045-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
  • The effectiveness of reduced-intensity conditioning allogeneic stem cell transplantation (allo- RIC) compared with high-dose chemotherapy followed by autologous stem cell transplantation (auto-SCT) in Hodgkin's disease (HD) and in non-Hodgkin's lymphoma (NHL) patients remains poorly defined.
  • The purpose of the study was to demonstrate the usefulness of auto-SCT or allo-SCT, employing a RIC regimen in refractory or relapsed NHL or HD patients.
  • We analyzed the outcome of 71 patients with advanced disease.
  • Twenty-three NHL and 14 HD patients received an allo-RIC using fludarabine, cyclophosphamide, and low-dose busulfan as the conditioning regimen.
  • Sixteen NHL and 18 HD patients received auto-SCT using cyclophosphamide and etoposide as conditioning regimen.
  • The relapse rate was higher in autografted patients, both in NHL and HD.
  • Both auto-SCT and allo-RIC appear to be valid treatments for poor-risk patients with relapsed or refractory lymphoma who could not otherwise be cured with conventional salvage regimens.
  • [MeSH-major] Ambulatory Care. Hematopoietic Stem Cell Transplantation / methods. Lymphoma / prevention & control. Lymphoma / surgery. Transplantation, Autologous / methods. Transplantation, Homologous / methods
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Transplantation Conditioning / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20490794.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Josting A, Rudolph C, Mapara M, Glossmann JP, Sieniawski M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Kisro J, Metzner B, Berdel WE, Diehl V, Engert A: Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol; 2005 Jan;16(1):116-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
  • BACKGROUND: We designed a dose- and time-intensified high-dose sequential chemotherapy regimen for patients with relapsed and refractory Hodgkin lymphoma (HD).
  • PATIENTS AND METHODS: Eligibility criteria included age 18-65 years, histologically proven primary progressive (PD) or relapsed HD.
  • Treatment consisted of two cycles DHAP (dexamethasone, high-dose cytarabine, cisplatinum); patients with chemosensitive disease received cyclophosphamide followed by peripheral blood stem cell harvest; methotrexate plus vincristine, etoposide and BEAM plus peripheral blood stem cell transplantation (PBSCT).
  • CONCLUSION: Based on the promising results of this study, a prospective randomized European intergroup study was started comparing this intensified regimen with two courses of DHAP followed by BEAM (HD-R2 protocol).

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Oncol. 2008 Aug;19(8):1515. Sienawski, M [corrected to Sieniawski, M]
  • (PMID = 15598948.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Smardova L, Engert A, Haverkamp H, Raemakers J, Baars J, Pfistner B, Diehl V, Josting A: Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma; 2005 Jul;46(7):1017-22
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease.
  • High-dose chemotherapy followed by autologous stem cell transplantation can improve the outcome of relapsed and refractory Hodgkin's disease (HD) patients.
  • The objective of the trial was to determine the mobilizing potential of the DHAP salvage regimen (dexamethasone, cytarabine, cisplatin) for the collection of peripheral blood stem cells (PBSC) in patients with relapsed HD.
  • These results demonstrate that the salvage chemotherapy regimen, such as DHAP combined with G-CSF, can be successfully used to mobilize PBSC in HD patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cells / metabolism. Hodgkin Disease / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / drug effects. Cisplatin / therapeutic use. Cytarabine / therapeutic use. Dexamethasone / therapeutic use. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Prognosis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019552.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; DHAP protocol
  •  go-up   go-down


19. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE: Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant; 2005 May;35(10):943-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
  • A total of 40 patients with relapsed/refractory Hodgkin's disease (HD) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) from an HLA-identical sibling (n=20) or a matched unrelated donor (n=20).
  • Disease status at allo-SCT was refractory relapse (n=14) or sensitive relapse (n=26).
  • In all, 16 patients expired (TRM n=8, disease progression n=8).
  • RIC allo-SCT is feasible in relapsed/refractory HD patients with a low TRM.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Female. Graft vs Host Disease / etiology. Humans. Leukocyte Transfusion. Male. Middle Aged. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806128.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Berrak SG, Pearson M, Berberoğlu S, Ilhan IE, Jaffe N: High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer; 2005 Mar;44(3):215-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
  • BACKGROUND: Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor.
  • PROCEDURE: HD-IFX was administered as described by Patel SR: J Clin Oncol 1997;15:2378.
  • Provided a response was obtained after two to four courses, treatment was continued for an additional eight courses unless progressive disease or an untoward event, for example, renal failure occurred.
  • Five patients were disease free at 15+ to 63+ months after induction and maintenance therapy.
  • CONCLUSIONS: HD-IFX is effective in patients who have failed conventional chemotherapy including IFX (9 g/m(2)).
  • Improved disease-free survival was achieved in 30% of patients.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Drug Administration Schedule. Female. Humans. Kidney Failure, Chronic / chemically induced. Male. Neoplasms, Second Primary / drug therapy. Recurrence. Treatment Outcome


21. Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR: Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Eur J Haematol; 2007 Feb;78(2):93-101
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
  • High-dose chemotherapy (HD-CT) with autologous stem cell transplantation is considered to be the treatment of choice for relapsed high-grade non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) patients, but the optimal treatment has not yet been defined.
  • We evaluated a salvage treatment regimen consisting of conventional cycles with ifosfamide, etoposide, cytarabine, and dexamethasone (IVAD) followed by two cycles of HD-CT consisting of cyclophosphamide, melphalan, and etoposide (CMV) with autologous stem cell support in patients with relapsed or refractory NHL (n = 59) and HL (n = 16).
  • Response to IVAD was complete remission (CR) in 16 patients (21%), partial remission (PR) in 39 patients (52%), stable disease (SD) in 18 patients (24%), and progressive disease (PD) in two patients (2.7%).
  • Of 70 patients treated with HD-CT, 41 patients (59%) showed a CR, 20 patients a PR (29%), eight patients a SD (11%), and one patient a PD (1.4%).
  • In multivariate analysis, an International Prognostic Index of > or = 2 and resistant disease to first-line chemotherapy were poor independent prognostic factors for the subgroup of patients with NHL.
  • In conclusion, these results indicate that IVAD/CMV is feasible as a salvage therapy for lymphoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / therapy. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation. Salvage Therapy
  • [MeSH-minor] Adult. Bone Marrow Diseases / chemically induced. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Cytarabine / administration & dosage. Cytarabine / therapeutic use. Dexamethasone / administration & dosage. Dexamethasone / therapeutic use. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Etoposide / therapeutic use. Female. Follow-Up Studies. Gastrointestinal Diseases / chemically induced. Hodgkin Disease / drug therapy. Hodgkin Disease / surgery. Hodgkin Disease / therapy. Humans. Ifosfamide / administration & dosage. Ifosfamide / therapeutic use. Kaplan-Meier Estimate. Male. Melphalan / administration & dosage. Melphalan / therapeutic use. Middle Aged. Neutropenia / chemically induced. Recurrence. Remission Induction. Sepsis / etiology. Sepsis / mortality. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313557.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


22. Hahn T, Benekli M, Wong C, Moysich KB, Hyland A, Michalek AM, Alam A, Baer MR, Bambach B, Czuczman MS, Wetzler M, Becker JL, McCarthy PL: A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant; 2005 Mar;35(6):557-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
  • There are several prognostic models for Hodgkin's disease (HD) patients, but none evaluating patient characteristics at time of blood and marrow transplantation (BMT).
  • We developed a prognostic model for event-free survival (EFS) post-BMT based on HD patient characteristics measured at the time of autologous (auto) or allogeneic (allo) BMT.
  • Between 1/1991 and 12/2001, 64 relapsed or refractory HD patients received an auto (n=46) or allo (n=18) BMT.
  • Significant multivariate predictors of shorter EFS were chemotherapy-resistant disease, KPS <90 and > or =3 chemotherapy regimens pre-BMT.
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Peripheral Blood Stem Cell Transplantation. Prognosis
  • [MeSH-minor] Adult. Cause of Death. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Graft Survival. Humans. Male. Middle Aged. Models, Theoretical. Multivariate Analysis. Salvage Therapy. Survival Analysis. Time. Transplantation, Autologous. Transplantation, Homologous


23. Viviani S, Di Nicola M, Bonfante V, Di Stasi A, Carlo-Stella C, Matteucci P, Magni M, Devizzi L, Valagussa P, Gianni AM: Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leuk Lymphoma; 2010 Jul;51(7):1251-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
  • The introduction of high-dose (HD) chemotherapy (CT) and autologous stem cell (ASCT) or bone marrow transplant (ABMT) in the last two decades has improved the prognosis of patients with refractory or relapsed Hodgkin lymphoma (HL) over conventional-dose salvage CT.
  • To evaluate the outcome of adult patients with HL treated with HD CT and ASCT or ABMT after failure or relapse from first-line treatment with CT +/- radiotherapy, we report the results of a retrospective analysis in 82 consecutive patients given HD CT and autologous transplant as second-line therapy between October 1984 and December 2006.
  • Seventy-three patients with chemoresponsive disease underwent the myeloablative phase, while eight patients had progressive disease during cytoreductive CT.
  • These long-term results confirm that HD CT and ASCT or ABMT was feasible, safe, and very effective.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Hodgkin Disease / therapy. Peripheral Blood Stem Cell Transplantation. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Time Factors. Transplantation, Autologous. Treatment Outcome. Young Adult


24. Lotz JP, Bui B, Gomez F, Théodore C, Caty A, Fizazi K, Gravis G, Delva R, Peny J, Viens P, Duclos B, De Revel T, Curé H, Gligorov J, Guillemaut S, Ségura C, Provent S, Droz JP, Culine S, Biron P, Groupe d'Etudes des Tumeurs Uro-Génitales (GETUG): Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol; 2005 Mar;16(3):411-8
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.
  • BACKGROUND: High-dose chemotherapy (HD-CT) is able to circumvent platinum resistance of resistant/refractory germ-cell tumors (GCTs), but expectancy of cure remains low.
  • MATERIALS AND METHODS: Patients with relapsed poor-prognosis GCTs were scheduled to receive two cycles combining epirubicin and paclitaxel (Taxol) followed by three consecutive HD-CT supported by stem cell transplantation [one course combining cyclophosphamide, 3 g/m(2) + thiotepa, 400 mg/m(2), followed by two ICE regimens (ifosfamide, 10 g/m(2), carboplatin, AUC 20, etoposide, 1500 mg/m(2))].
  • The 'Beyer' prognostic score predicted the outcome after HD-CT.
  • CONCLUSION: Although our results warrant further studies on HD-CT in relapsed poor prognosis GCTs, patients with a Beyer score >2 did not benefit from this approach and should not be enrolled in HD-CT trials.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15659420.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


25. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I: ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant; 2006 Feb;37(3):277-82
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
  • From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT).
  • DLCL 49: HD 78.
  • Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Hodgkin Disease / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Blood Component Removal / methods. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Recurrence. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400345.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


26. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE: Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol; 2005 Apr 1;23(10):2240-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
  • PURPOSE: We investigated the efficacy and safety of administering high-dose rituximab (HD-R) in combination with high-dose carmustine, cytarabine, etoposide, and melphalan chemotherapy and autologous stem-cell transplantation (SCT) in patients with recurrent B-cell aggressive non-Hodgkin's lymphoma (NHL).
  • HD-R of 1,000 mg/m(2) was administered again days 1 and 8 after transplantation.
  • Disease-free survival was 67% (95% CI, 51% to 79%) for the study group and 43% (95% CI, 26% to 60%) for the control group (P = .004).
  • CONCLUSION: The results of this study suggest that using HD-R and autologous SCT is a feasible and promising treatment for patients with B-cell aggressive NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Carmustine / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Melphalan / administration & dosage. Middle Aged. Rituximab. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800314.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


27. Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA: Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol; 2006 May 1;24(13):2105-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
  • Twenty-four patients had mantle cell lymphoma (MCL), 13 had follicular lymphoma (FL), six had lymphoplasmacytic lymphoma, six had Hodgkin's disease (HD), and one each had diffuse large B-cell lymphoma and adult T-cell leukemia/lymphoma.
  • Two patients with Waldenström's macroglobulinemia and one patient with HD achieved a PR.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma / drug therapy. Pyrazines / therapeutic use. Tumor Necrosis Factor-alpha / analysis
  • [MeSH-minor] Adult. Aged. Bortezomib. Cell Line, Tumor. Cell Survival / drug effects. Cytokines / blood. Doxorubicin / pharmacology. Female. Humans. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16606971.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501974
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Cytokines; 0 / Pyrazines; 0 / Tumor Necrosis Factor-alpha; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin
  •  go-up   go-down


28. Wimmer RS, Chauvenet AR, London WB, Villaluna D, de Alarcon PA, Schwartz CL: APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial. Pediatr Blood Cancer; 2006 Mar;46(3):320-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial.
  • BACKGROUND: MOPP (mechlorethamine, vincristine, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) are effective therapies for Hodgkin disease (HD) that may cause long-term toxicities in children.
  • We evaluated this regimen for patients with recurrent or refractory disease.
  • METHODS: Patients with recurrent Hodgkin disease who were <or=21 years of age and had previously received standard alkylating agent and doxorubicin-based therapy, were treated with APE chemotherapy (cytosine arabinoside 750 mg/m(2), cisplatin 15 mg/m(2), etoposide 20 mg/m(2)) every 12 hr, administered three or four times per cycle.
  • RESULTS: Thirty-one patients in first (n = 25) or second (n = 6) relapse of Hodgkin disease were eligible and evaluable.
  • The Children's Oncology Group is using a similar regimen to augment therapy for slow responders on a current Hodgkin disease trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Male. Recurrence. Remission Induction. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200630.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 410 CA 30969
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Kuruvilla J, Song K, Mollee P, Panzarella T, McCrae J, Nagy T, Crump M, Keating A: A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology; 2006 Feb;11(1):25-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma.
  • INTRODUCTION: Patients with Hodgkin's Lymphoma (HL) who relapse or progress after primary therapy and subsequent high dose chemotherapy with autologous stem cell transplantation (ASCT) cannot be cured with conventional treatment.
  • We combined thalidomide (THAL), an agent with anti-angiogenic and immunomodulatory properties, with vinblastine, which is active after ASCT, to determine the objective response rate, improvement in B symptoms and toxicity in patients with refractory HD.
  • METHODS: Patients were eligible if they HD that progressed after chemotherapy and ASCT or had declined or were ineligible for curative therapy.
  • PATIENT CHARACTERISTICS: relapsed after ASCT: 7; median number of prior chemotherapy regimens: 3 (range 1-5); median time to progression post-ASCT: 7 months (range 2-29).
  • Four patients had a partial response to treatment (response rate 36%); two patients had stable disease.
  • Five had disease progression within 3 months of starting treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / therapy. Palliative Care. Stem Cell Transplantation
  • [MeSH-minor] Administration, Oral. Adult. Female. Humans. Injections, Intravenous. Male. Middle Aged. Remission Induction. Thalidomide / administration & dosage. Thalidomide / adverse effects. Transplantation, Autologous. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16522545.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


30. Greco M, Valsecchi M, Niccodemi C, Presas J, Corrado C, Winkel M: [Limphomatous meningitis as recurrence site in Hodgkin's disease]. Medicina (B Aires); 2006;66(4):332-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Limphomatous meningitis as recurrence site in Hodgkin's disease].
  • [Transliterated title] Meningitis linfomatosa como sitio de recaída en la enfermedad de Hodgkin.
  • Intracraneal manifestations of Hodgkin's Disease (HD) are extremely rare, with an estimated incidence rate of approximately 0.5%.
  • We describe a case of a 40 year-old male with mixed cellularity type HD who developed neurological manifestations as relapsed disease.
  • The patient died from progressive disease refractory to third line chemotherapy.
  • We review the clinical features and differential diagnosis of leptomeningeal metastases in Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / pathology. Meningeal Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dacarbazine / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Leukoencephalopathy, Progressive Multifocal / chemically induced. Leukoencephalopathy, Progressive Multifocal / pathology. Magnetic Resonance Imaging. Male. Paraneoplastic Syndromes / pathology. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977969.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; ESHAP regimen
  •  go-up   go-down


31. Fraunholz IB, Gerstenhauer A, Böttcher HD: Results of postoperative (90)Sr radiotherapy of keloids in view of patients' subjective assessment. Strahlenther Onkol; 2005 Nov;181(11):724-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among 18 of the 41 patients (44%), who had answered the questionnaire, 19 of the 53 keloids treated (36%) had relapsed.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Patient Satisfaction. Recurrence. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. STRONTIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16254708.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] YZS2RPE8LE / Strontium
  •  go-up   go-down


32. Huang HQ, Cai QC, Shi YX, Lin XB, Wei J, Guo Y, Pan ZH: [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)]. Ai Zheng; 2006 Aug;25(8):1023-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 19 Non-hodgkin Lymphoma (NHL), 3 Hodgkin Lymphoma (HD) and 2 rhabdomyosarcoma.
  • RESULTS: 75% of the cases achieved CR while 4.17% were progression of disease (PD) and 16.67% were relapsed during the median follow-up time of 12 (2-60) months.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / immunology. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. CD4-CD8 Ratio. CD4-Positive T-Lymphocytes / immunology. Cytokine-Induced Killer Cells / transplantation. Cytokines / metabolism. Female. Follow-Up Studies. Humans. Interferon-alpha / therapeutic use. Interleukin-2 / therapeutic use. Male. Middle Aged. Remission Induction. Th1 Cells / immunology. Th2 Cells / immunology. Thymus Extracts / therapeutic use. Transplantation Conditioning. Transplantation, Autologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965687.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / TFX; 0 / Thymus Extracts
  •  go-up   go-down


33. Bug G, Atta J, Klein SA, Hertenstein B, Bergmann L, Boehrer S, Mousset S, Hoelzer D, Martin H: High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation. Ann Hematol; 2005 Oct;84(11):748-54
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a pilot study high-dose melphalan (HD-Mel, 200 mg/m2) and autologous stem cell transplantation (ASCT) were administered to 14 patients (median age 52, range 29-60 years) with acute myeloid leukaemia (AML) in first relapse after a previous ASCT in first complete remission (n=11) or chemotherapy (n=3).
  • A first cohort of five patients received HD-Mel as salvage therapy after a previous cycle of mitoxantrone, topotecan and cytarabine (MTC) had failed in four out of five patients, while a second cohort of nine patients received HD-Mel in untreated relapse.
  • No treatment-related mortality was observed after HD-Mel.
  • Thirteen (93%) patients were able to proceed to a dose-reduced allogeneic stem cell transplantation (allo-SCT) from human-leucocyte-antigens-compatible unrelated (n=12) or sibling donors (n=1) in CR2 (n=11) or poor recovery/relapse (n=2) after a median of 2 (1.7-4.5) months following HD-Mel.
  • Three MTC-refractory patients, but none of the upfront HD-Mel patients, died due to an allograft-related non-relapse cause.
  • Nine patients are alive in CR2 after a median of 6 (2-49) months after HD-Mel and a median of 4 (0.6-47) months after a sequential allo-SCT.
  • Our results highly encourage to further investigate HD-Mel and ASCT as a promising salvage regimen for relapsed AML patients for whom autologous peripheral blood stem cells are available.
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Female. Humans. Karyotyping. Male. Middle Aged. Recurrence. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001243.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


34. Chua HD, Hägg MB, Cheung LK: Cleft maxillary distraction versus orthognathic surgery--which one is more stable in 5 years? Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jun;109(6):803-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In the CO group, the maxilla relapsed backward and upward, whereas in the DO group, it advanced more forward and downward over 5 years.
  • [MeSH-minor] Cephalometry. Female. Follow-Up Studies. Humans. Male. Malocclusion, Angle Class III / etiology. Malocclusion, Angle Class III / surgery. Osteotomy, Le Fort / methods. Secondary Prevention. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cleft Lip and Palate.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20299247.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Bishton MJ, Lush RJ, Byrne JL, Russell NH, Shaw BE, Haynes AP: Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol; 2007 Mar;136(5):752-61
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
  • A total of 143 patients with relapsed (n = 90), primary refractory (n = 32) and first line chemotherapy responsive (n = 21) non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD) were treated with IVE (ifosphamide, etoposide and epirubicin) chemotherapy with the intent to proceed to high-dose therapy with either autologous or allogeneic transplantation, following peripheral blood stem cell mobilisation.
  • Subgroup analysis showed overall response rates of 93.1% for HD with a 5-year OS and EFS of 62% and 52% respectively, while NHL showed response rates of 78.0% with 5-year OS and EFS of 50% and 39% respectively.
  • We conclude that IVE has a high response rate across a range of refractory and relapsed lymphoma with acceptable toxicity and excellent PBSC mobilising characteristics.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Mobilization / methods. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Epirubicin / adverse effects. Epirubicin / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Ifosfamide / adverse effects. Ifosfamide / therapeutic use. Male. Middle Aged. Neutropenia / chemically induced. Peripheral Blood Stem Cell Transplantation. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313378.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide; IEV protocol
  •  go-up   go-down


36. Xiao T, Xia LX, Yang ZH, He CD, Gao XH, Chen HD: Narrow-band ultraviolet B phototherapy for early stage mycosis fungoides. Eur J Dermatol; 2008 Nov-Dec;18(6):660-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upon discontinuation of treatment, four patients with complete response relapsed in a mean time to relapse of 5 months.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955199.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


37. Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT: Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs; 2008 Apr;31(4):295-302
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven (50%) of the 14 patients were non-responders, two of which relapsed after discontinuation of therapy.
  • Two patients died (week 4 and 14) of causes related to cardiovascular disease, which was frequent in our cohort.
  • CONCLUSIONS: Results from this study showed that about one-third of HD patients achieved sustained virological response with pegylated-interferon-alpha-2a plus low-dose ribavirin; however, tolerance to antiviral treatment was unsatisfactory.
  • Prospective, controlled clinical trials of combined antiviral therapy targeted at HCV in chronic kidney disease population are indicated.
  • [MeSH-minor] Adult. Aged. Anti-Retroviral Agents / therapeutic use. Drug Therapy, Combination. Female. HIV Infections / complications. HIV Infections / drug therapy. Hepacivirus / genetics. Humans. Male. Middle Aged. Patient Dropouts. Prospective Studies. RNA, Viral / blood. Recombinant Proteins. Recurrence. Time Factors. Treatment Outcome. Viral Load

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432584.001).
  • [ISSN] 0391-3988
  • [Journal-full-title] The International journal of artificial organs
  • [ISO-abbreviation] Int J Artif Organs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 49717AWG6K / Ribavirin; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


38. Provencio M, Salas C, Millán I, Cantos B, Sánchez A, Bellas C: Late relapses in Hodgkin lymphoma: a clinical and immunohistochemistry study. Leuk Lymphoma; 2010 Sep;51(9):1686-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late relapses in Hodgkin lymphoma: a clinical and immunohistochemistry study.
  • Survival in Hodgkin lymphoma (HL) has significantly increased, and most relapses occur in the first 2 years.
  • We studied 534 patients with HD and found 150 relapses (28%), 30 of which occurred 5 years after the end of treatment.
  • Seven of 30 patients relapsed with a different histological type.
  • There were no statistically significant differences in survival between those patients with a late relapse and new remission and those who never relapsed.
  • Long-term survival was not significantly different in relapsed patients with remission after treatment compared with patients who never relapsed.
  • [MeSH-major] Hodgkin Disease / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Remission Induction. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629526.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


39. Alexandrescu DT, Karri S, Wiernik PH, Dutcher JP: Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease. Leuk Lymphoma; 2006 Apr;47(4):641-56
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease.
  • Advanced-stage or relapsed/refractory Hodgkin's disease (HD) has a poor prognosis despite aggressive chemotherapy regimens and the use of high-dose therapy with autologous stem cell support.
  • Mitoxantrone, vinblastine and CCNU (lomustine) (MVC) combines the most effective chemotherapeutic agents of previous regimens for poor prognosis HD, and eliminates marginally active agents with unnecessary toxicities, such as bleomycin and dacarbazine.
  • Sixty-eight patients with HD (23 newly diagnosed and 45 with relapsed/refractory disease, one patient treated both de novo and years later in relapse) were treated with the MVC regimen (mitoxantrone 8 mg/m(2)/day i.v. days 1 - 3; vinblastine 8 m/m(2)/day days 1 and 22; and CCNU (lomustine) 100 mg/m(2) on day 1, repeated at 6 - 8 weeks) in a single-arm Phase II study.
  • Four secondary myeloid leukemias occurred, three in de novo, and one in the relapsed/refractory group, at a median follow-up of 14 years.
  • MVC regimen for HD is highly active, for both de novo and relapsed/refractory disease, with high response rates and survival that compare favourably with the results obtained by high-dose therapy with stem-cell transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lomustine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / therapeutic use. Vinblastine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690523.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA14958; United States / NCI NIH HHS / CA / P30CA13330
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5V9KLZ54CY / Vinblastine; 7BRF0Z81KG / Lomustine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


40. Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA, Cancer and Leukemia Group B: Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol; 2009 Apr;63(5):793-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the efficacy and toxicity of the topoisomerase I inhibitor, 9-aminocamptothecin (9-AC), in patients with relapsed lymphoma and to correlate 9-AC plasma concentrations with response and toxicity.
  • METHODS: Eligible patients had relapsed Hodgkin lymphoma (HL) treated with one or two prior regimens, low grade non-Hodgkin's lymphoma (NHL) treated with one or two prior regimens, or aggressive NHL treated with one prior regimen.
  • RESULTS: CALGB 9551 accrued 37 patients from April 1996 through October 2000; one patient with HD, 18 patients with indolent lymphoma, and 17 patients with aggressive lymphoma.
  • The patient with HD did not respond.
  • CONCLUSION: Single agent 9-AC has modest activity in aggressive non-Hodgkin's lymphomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Camptothecin / analogs & derivatives. Hodgkin Disease / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Resistance, Neoplasm. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Prognosis. Salvage Therapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648813.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5MB77ICE2Q / 9-aminocamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


41. Rüffer JU, Ballova V, Glossmann J, Sieber M, Franklin J, Nogova L, Diehl V, Josting A, German Hodgkin Study Group: BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Leuk Lymphoma; 2005 Nov;46(11):1561-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.
  • Patients with early stage favorable Hodgkin's disease who relapse after extended field radiotherapy have satisfactory results.
  • We retrospectively analysed patients with relapsed HD after initial radiation therapy alone to determine treatment outcome and prognostic factors.
  • 107 patients relapsed and received salvage therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Databases, Factual. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiation Dosage. Radiotherapy / methods. Remission Induction. Retrospective Studies. Survival Analysis. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236610.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol; CVPPABO protocol
  •  go-up   go-down


42. Guo C, Chu X, Shi Y, He W, Li L, Wang L, Wang Y, Peng J, Hou M: Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol; 2007 Nov;27(6):557-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the possible correcting of T helper (Th) cytokine profiles by high-dose dexamethasone (HD-DXM) therapy in chronic idiopathic thrombocytopenic purpura (ITP) with active disease, we determined the plasma levels of IFN-gamma, IL-2, IL-4, IL-10, and TGF-beta1 in 52 patients before and after oral administration of 40 mg/day DXM for four consecutive days.
  • After HD-DXM treatment, IFN-gamma and IL-2 were decreased (P < 0.01), whereas IL-4 and IL-10 were increased (P < 0.05).
  • There was no significant difference between the HD-DXM-treated patients and the normal controls (P > 0.05).
  • TGF-beta1 was also increased (P < 0.01) after HD-DXM treatment, but still lower than that of the normal controls (P < 0.05).
  • During following-up, the cytokine profiles in the SRs remained stable compared to the posttreatment level (P > 0.05), but IFN-gamma and IL-2 levels raised up, and IL-4, IL-10, and TGF-beta1 levels reduced again in the relapsed patients (P < 0.01).
  • Our data demonstrate that HD-DXM is an effective initial therapy for ITP, and the Th1 cytokine dominance could be corrected by HD-DXM.
  • [MeSH-minor] Adolescent. Adult. Aged. Chronic Disease. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Idiopathic thrombocytopenic purpura.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17619126.001).
  • [ISSN] 0271-9142
  • [Journal-full-title] Journal of clinical immunology
  • [ISO-abbreviation] J. Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Cytokines; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


43. Zinzani PL, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E, Stefoni V, Castellucci P, Fina M, Farshad M, Pileri S, Baccarani M: Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol; 2006 Aug;17(8):1296-300
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.
  • BACKGROUND: It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients.
  • PATIENTS AND METHODS: Between June 2003-September 2004, in our institute, 40 newly-diagnosed patients with advanced stage HD were consecutively treated with ABVD chemotherapy for six cycles.
  • After treatment, among eight patients who were PET-2+, seven showed refractory disease and one had relapse after 3 months.
  • All four patients with MRU at the PET-2 became PET- during the further four cycles and, after treatment, three were in complete response (CR) and one relapsed after 5 months.
  • CONCLUSIONS: The PET use for early (after two cycles) response assessment in HD patients is a significant step forward and has the potential to help physicians make crucial decisions about further treatment.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766583.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


44. Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M, Banna G, Tirelli U, Soligo D, Santoro A: Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Eur J Haematol; 2007 Apr;78(4):322-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
  • BACKGROUND: We analysed the feasibility and efficacy of allogeneic stem cell transplantation (allo-SCT) with reduced-intensity conditioning (RIC) in patients with refractory or progressive Hodgkin's disease (HD) after high-dose chemotherapy (HDCT).
  • PATIENTS AND METHODS: Fourteen patients with HD received allo-SCT with RIC: eleven patients had a human leucocytes antigen-identical related donor and three a matched unrelated donor.
  • Six had chemoresistant disease and eight had chemosensitive one at the time of transplantation.
  • Grade II acute graft-vs.-host disease (GvHD) developed in six of the 14 patients (43%).
  • Estimated overall survival at 1 and 2 yr was 93% and 73%, respectively, for the whole population, 83% and 44% respectively for patients with chemoresistant disease and 100% for those with chemosensitive disease.
  • Estimated progression-free survival at 1 yr was 36%; 62.5% for chemosensitive patients and 0% for those with chemoresistant disease.
  • CONCLUSIONS: In conclusion, allo-SCT with fludarabine-based RIC is a feasible procedure, without TRM in HD patients relapsed and refractory after HDCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation / adverse effects. Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Disease Progression. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Graft vs Host Disease / therapy. Humans. Male. Middle Aged. Recurrence. Survival Rate. Transplantation, Autologous / adverse effects. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17253967.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


45. Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C: [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Orv Hetil; 2009 Oct 18;150(42):1937-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary central nervous system lymphoma is defined as an extranodal lymphoma arising in the central nervous system in the absence of systemic disease.
  • AIMS: In this retrospective survey we analyzed the result of combined treatment (systemic and intrathecal chemotherapy followed by consolidation radiotherapy) in patients with primary or relapsed central nervous system lymphomas diagnosed and treated in our hematological department between 1998-2009.
  • PATIENTS AND METHODS: During this period (mean follow-up of 13.2 months) from 427 patients with newly diagnosed non-Hodgkin's lymphomas, 22 primary central nervous system lymphoma was diagnosed (5.15%, 16 cerebral and 6 spinal cord lymphoma cases).
  • All central nervous system lymphoma specimens taken with neurosurgical resection or stereotaxic biopsies were confirmed histopathologically.
  • All cerebral lymphoma cases proved to be diffuse large B-cell of origin, while in epidural lymphomas low grade subtypes also occurred.
  • In cerebral lymphoma (every patients had supratentorial localization) the following combined therapy protocol was used: up to three courses of high dose methotrexate (HD MTX 3g/m 2 in a single dose for 4 hours lasting drop-infusion) were given at 4-week intervals, followed by leucovorin-rescue 24 hours after MTX infusion.
  • Intrathecal combination of methotrexate, cytosin-arabinosid and dexamethasone was given three times after HD MTX infusion.
  • In relapse or resistant cases, salvage regimen was applied: HD MTX course combined with high dose cytosin-arabinosid (HD Ara-C) 3g/m 2 /dose b.i.d. over 4 h c.i., repeated in three cycles every four weeks.
  • RESULTS: Complete remission has been achieved in 9 patients with cerebral and in 4 patients with spinal cord lymphoma (13/22; 59.0%), however, one relapsed patient became resistant and later expired, despite salvage therapy.
  • Primarily 9 patients were not evaluable for response: 5 received only one or two HD MTX because of side effects, 4 patients died due to progression of the disease.
  • Mean of the overall survival (OS) in cerebral lymphoma was 19.5 (3-46, median of 10) months, in epidural group 14.1 (2-76, median of 5) months, whilst mean time to progression (TTP) was 4.5 (2-6.5, median of 4 months).
  • CONCLUSION: In primary central nervous system lymphoma, basic treatment HD methotrexate together with intrathecal combination of methotrexate + cytosin-arabinosid + dexamethasone followed by whole-brain irradiation of at least 30 Gy could produce a medium response rate in our study.
  • In case of relapse or progression, other salvage regimens containing HD Ara-C alternating with HD MTX could reduce the treatment failure, as well.
  • After therapy PET/CT was negative in five patients with prolonged disease-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Cranial Irradiation. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Epidural Space. Female. Humans. Hungary / epidemiology. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Positron-Emission Tomography. Prednisone / administration & dosage. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Rituximab. Salvage Therapy / methods. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19812012.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


46. Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A: Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol; 2006 Jan;78(1):1-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease.
  • BACKGROUND: Short course chemotherapy followed by radiotherapy is a standard treatment for early Hodgkin's disease.
  • PATIENTS AND METHODS: From 1980 to 1996, 61 patients with stage I and II supradiaphragmatic Hodgkin's disease were treated with chemotherapy alone at the Royal Marsden Hospital.
  • RESULTS: After a median follow-up of 6.5 years, 24 patients had relapsed giving a 5-year relapse rate of 40%.
  • Twenty patients (83%) relapsed in the initially involved sites of disease and this was the sole site of recurrence in 11 (45%) of patients.
  • Review of detailed imaging data (available in 9 out of 11 patients with recurrences in initial sites of disease) showed that the relapses were always in the initially involved nodes.
  • CONCLUSION: After chemotherapy alone in early stage HD most initial recurrences are nodal.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309770.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down






Advertisement